MabGenesis Building On Efficient Antibody Isolation Platform
Oncology One Focus Of Young Japan Venture
Antibody-focused MabGenesis is building on a technology platform it says can efficiently produce highly targeted antibodies against challenging targets. The Japanese venture is looking for both its first major deal and potentially an IPO within the next five years.
